Abstract
Introduction: The objective of this study was to assess the relationship between longitudinal changes in the uterine Doppler velocimetry and the maternal profile of angiogenic factors in the third trimester and to assess their ability to predict term preeclampsia (PE). Methods: A cohort of low-risk pregnant women was scheduled for a uterine Doppler evaluation and measurement of the circulating levels of angiogenic factors at ∼30 and ∼36 weeks. The performance of both parameters and their change over time in predicting term PE was evaluated. Results: A total of 1,191 women were analyzed, of which 28 (2.4%) women developed term PE. At ∼30 weeks, a model including the sFlt-1/PlGF (fms-like tyrosine kinase-1/placental growth factor) ratio and the uterine Doppler explained 16.2% of the uncertainty of developing term PE, while at ∼36 weeks, the same variables explained 25.2% [p < 0.001]. The longitudinal changes of both predictors had an R2 of 26.8%, which was not different from that of the ∼36 weeks evaluation [p = 0.45]. The area under the curve (AUC) of the ∼36 weeks ratio was significantly higher than at ∼30 weeks (0.86 [0.77–0.94] vs. 0.81 [0.73–0.9]; p = 0.043). The AUC of the longitudinal change of the ratio (0.85 [0.77–0.94]) did not differ from that of at ∼36 weeks (p = 0.82). At ∼36 weeks, for a 10% of false positives, the ratio had a detection rate of 71.4%. Conclusion: A cross-sectional measurement of the sFlt-1/PlGF ratio outperforms uterine Doppler in predicting term PE. The combination of both markers does not improve such prediction, nor the evaluation of the longitudinal changes between weeks.
Journal Section:
Prenatal Diagnosis
References
1.
Melchiorre
K
, Giorgione
V
, Thilaganathan
B
. The placenta and preeclampsia: villain or victim
. Am J Obstet Gynecol
. 2022
;226
(2S
):S954
–62
. 2.
Högberg
U
. The World Health Report 2005: make every mother and child count–including Africans
. Scand J Public Health
. 2005
;33
(6
):409
–11
. 3.
Poon
LC
, Shennan
A
, Hyett
JA
, Kapur
A
, Hadar
E
, Divakar
H
, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention
. Int J Gynaecol Obstet
. 2019
;145
(Suppl 1
):1
–33
. 4.
Mifsud
W
, Sebire
NJ
. Placental pathology in early-onset and late-onset fetal growth restriction
. Fetal Diagn Ther
. 2014
;36
(2
):117
–28
. 5.
Ogge
G
, Chaiworapongsa
T
, Romero
R
, Hussein
Y
, Kusanovic
JP
, Yeo
L
, et al. Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia
. J Perinat Med
. 2011
;39
(6
):641
–52
. 6.
Chilumula
K
, Saha
PK
, Muthyala
T
, Saha
SC
, Sundaram
V
, Suri
V
. Prognostic role of uterine artery Doppler in early- and late-onset preeclampsia with severe features
. J Ultrasound
. 2021
;24
(3
):303
–10
. 7.
Rana
S
, Lemoine
E
, Granger
JP
, Karumanchi
SA
. Preeclampsia: pathophysiology, challenges, and perspectives
. Circ Res
. 2019
;124
(7
):1094
–112
. 8.
Gyselaers
W
, Thilaganathan
B
. Preeclampsia: a gestational cardiorenal syndrome
. J Physiol
. 2019
;597
(18
):4695
–714
. 9.
Stepan
H
, Hund
M
, Andraczek
T
. Combining biomarkers to predict pregnancy complications and redefine preeclampsia: the angiogenic-placental syndrome
. Hypertens
. 2020
;75
(4
):918
–26
. 10.
Panaitescu
A
, Ciobanu
A
, Syngelaki
A
, Wright
A
, Wright
D
, Nicolaides
KH
. Screening for pre-eclampsia at 35-37 weeks’ gestation
. Ultrasound Obstet Gynecol
. 2018
;52
(4
):501
–6
. 11.
Gomez-Roig
MD
, Mazarico
E
, Sabria
J
, Parra
J
, Oton
L
, Vela
A
. Use of placental growth factor and uterine artery Doppler pulsatility index in pregnancies involving intrauterine fetal growth restriction or preeclampsia to predict perinatal outcomes
. Gynecol Obstet Invest
. 2015
;80
(2
):99
–105
. 12.
Figueras
F
, Gratacos
E
, Rial
M
, Gull
I
, Krofta
L
, Lubusky
M
, et al. Revealed versus concealed criteria for placental insufficiency in an unselected obstetric population in late pregnancy (RATIO37): randomised controlled trial study protocol
. BMJ Open
. 2017
;7
(6
):e014835
. 13.
Hadlock
FP
, Harrist
RB
, Sharman
RS
, Deter
RL
, Park
SK
. Estimation of fetal weight with the use of head, body, and femur measurements: a prospective study
. Am J Obstet Gynecol
. 1985
;151
(3
):333
–7
. 14.
Stirnemann
J
, Villar
J
, Salomon
LJ
, Ohuma
E
, Ruyan
P
, Altman
DG
, et al. International estimated fetal weight standards of the INTERGROWTH-21(st) Project
. Ultrasound Obstet Gynecol
. 2017
;49
(4
):478
–86
. 15.
Robinson
HP
, Fleming
JE
. A critical evaluation of sonar “crown-rump length” measurements
. Br J Obstet Gynaecol
. 1975
;82
(9
):702
–10
. 16.
Bhide
A
, Acharya
G
, Baschat
A
, Bilardo
CM
, Brezinka
C
, Cafici
D
, et al. ISUOG Practice Guidelines (updated): use of Doppler velocimetry in obstetrics
. Ultrasound Obstet Gynecol
. 2021
;58
(2
):331
–9
. 17.
Brown
MA
, Magee
LA
, Kenny
LC
, Karumanchi
SA
, McCarthy
FP
, Saito
S
, et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis and management recommendations for international practice
. Pregnancy Hypertens
. 2018
;13
:291
–310
. 18.
Gómez
O
, Figueras
F
, Fernández
S
, Bennasar
M
, Martínez
JM
, Puerto
B
, et al. Reference ranges for uterine artery mean pulsatility index at 11-41 weeks of gestation
. Ultrasound Obstet Gynecol
. 2008
;32
(2
):128
–32
. 19.
DeLong
ER
, DeLong
DM
, Clarke-Pearson
DL
. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach
. Biometrics
. 1988
;44
(3
):837
–45
. 20.
Sovio
U
, Gaccioli
F
, Cook
E
, Hund
M
, Charnock-Jones
DS
, Smith
GCS
. Prediction of preeclampsia using the soluble fms-like tyrosine kinase 1 to placental growth factor ratio: a prospective cohort study of unselected nulliparous women
. Hypertens
. 2017
;69
(4
):731
–8
. 21.
MacDonald
TM
, Tran
C
, Kaitu’u-Lino
TJ
, Brennecke
SP
, Hiscock
RJ
, Hui
L
, et al. Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks’ gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study
. BMC Pregnancy Childbirth
. 2018
;18
(1
):354
. 22.
Döbert
M
, Wright
A
, Varouxaki
AN
, Mu
AC
, Syngelaki
A
, Rehal
A
, et al. STATIN trial: predictive performance of competing-risks model in screening for pre-eclampsia at 35-37 weeks’ gestation
. Ultrasound Obstet Gynecol
. 2022
;59
(1
):69
–75
. 23.
Park
HJ
, Kim
SH
, Jung
YW
, Shim
SS
, Kim
JY
, Cho
YK
, et al. Screening models using multiple markers for early detection of late-onset preeclampsia in low-risk pregnancy
. BMC Pregnancy Childbirth
. 2014
;14
:35
. 24.
Pfeffer
TJ
, Hilfiker-Kleiner
D
. Pregnancy and heart disease: pregnancy-associated hypertension and peripartum cardiomyopathy
. Curr Probl Cardiol
. 2018
;43
(9
):364
–88
. 25.
Patten
IS
, Rana
S
, Shahul
S
, Rowe
GC
, Jang
C
, Liu
L
, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy
. Nature
. 2012
;485
(7398
):333
–8
. 26.
Ives
CW
, Sinkey
R
, Rajapreyar
I
, Tita
ATN
, Oparil
S
. Preeclampsia-pathophysiology and clinical presentations: JACC state-of-the-art review
. J Am Coll Cardiol
. 2020
;76
(14
):1690
–702
. 27.
Poon
LCY
, Zaragoza
E
, Akolekar
R
, Anagnostopoulos
E
, Nicolaides
KH
. Maternal serum placental growth factor (PlGF) in small for gestational age pregnancy at 11(+0) to 13(+6) weeks of gestation
. Prenat Diagn
. 2008
;28
(12
):1110
–5
. 28.
Levine
RJ
, Maynard
SE
, Qian
C
, Lim
KH
, England
LJ
, Yu
KF
, et al. Circulating angiogenic factors and the risk of preeclampsia
. N Engl J Med
. 2004
;350
(7
):672
–83
. 29.
Chau
K
, Hennessy
A
, Makris
A
. Placental growth factor and pre-eclampsia
. J Hum Hypertens
. 2017
;31
(12
):782
–6
. 30.
Valiño
N
, Giunta
G
, Gallo
DM
, Akolekar
R
, Nicolaides
KH
. Biophysical and biochemical markers at 30-34 weeks’ gestation in the prediction of adverse perinatal outcome
. Ultrasound Obstet Gynecol
. 2016
;47
(2
):194
–202
. 31.
Sarno
M
, Wright
A
, Vieira
N
, Sapantzoglou
I
, Charakida
M
, Nicolaides
KH
. Ophthalmic artery Doppler in combination with other biomarkers in prediction of pre-eclampsia at 35-37 weeks’ gestation
. Ultrasound Obstet Gynecol
. 2021
;57
(4
):600
–6
. 32.
Andrietti
S
, Silva
M
, Wright
A
, Wright
D
, Nicolaides
KH
. Competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 35-37 weeks’ gestation
. Ultrasound Obstet Gynecol
. 2016
;48
(1
):72
–9
. 33.
Ciobanu
A
, Wright
A
, Panaitescu
A
, Syngelaki
A
, Wright
D
, Nicolaides
KH
. Prediction of imminent preeclampsia at 35-37 weeks gestation
. Am J Obstet Gynecol
. 2019
;220
(6
):584.e1
–1
. 34.
Stepan
H
, Hund
M
, Dilba
P
, Sillman
J
, Schlembach
D
. Elecsys® and Kryptor immunoassays for the measurement of sFlt-1 and PlGF to aid preeclampsia diagnosis: are they comparable
. Clin Chem Lab Med
. 2019
;57
(9
):1339
–48
. 35.
Cheng
YKY
, Poon
LCY
, Shennan
A
, Leung
TY
, Sahota
DS
. Inter-manufacturer comparison of automated immunoassays for the measurement of soluble FMS-like tyrosine kinase-1 and placental growth factor
. Pregnancy Hypertens
. 2019
;17
:165
–71
. 36.
Zeisler
H
, Llurba
E
, Chantraine
F
, Vatish
M
, Staff
AC
, Sennström
M
, et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia
. N Engl J Med
. 2016
;374
(1
):13
–22
. 37.
Lisonkova
S
, Joseph
KS
. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease
. Am J Obstet Gynecol
. 2013
;209
(6
):544.e1
–2
. 38.
Cluver
C
, Novikova
N
, Koopmans
CM
, West
HM
. Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
. Cochrane Database Syst Rev
. 2017
;1
(1
):CD009273
. 39.
Gallo
DM
, Wright
D
, Casanova
C
, Campanero
M
, Nicolaides
KH
. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks’ gestation
. Am J Obstet Gynecol
. 2016
;214
(5
):619.e1
–7
. 40.
Crovetto
F
, Figueras
F
, Triunfo
S
, Crispi
F
, Rodriguez-Sureda
V
, Dominguez
C
, et al. First trimester screening for early and late preeclampsia based on maternal characteristics, biophysical parameters, and angiogenic factors
. Prenat Diagn
. 2015
;35
(2
):183
–91
. 41.
Rolnik
DL
, Wright
D
, Poon
LC
, O’Gorman
N
, Syngelaki
A
, de Paco Matallana
C
, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia
. N Engl J Med
. 2017
;377
(7
):613
–22
. 42.
Döbert
M
, Varouxaki
AN
, Mu
AC
, Syngelaki
A
, Ciobanu
A
, Akolekar
R
, et al. Pravastatin versus placebo in pregnancies at high risk of term preeclampsia
. Circulation
. 2021
;144
(9
):670
–9
. 43.
Grobman
WA
, Rice
MM
, Reddy
UM
, Tita
ATN
, Silver
RM
, Mallett
G
, et al. Labor induction versus expectant management in low-risk nulliparous women
. N Engl J Med
. 2018
;379
(6
):513
–23
. 44.
Middleton
P
, Shepherd
E
, Morris
J
, Crowther
CA
, Gomersall
JC
. Induction of labour at or beyond 37 weeks’ gestation
. Cochrane Database Syst Rev
. 2020
;7
(7
):CD004945
. 45.
Chaemsaithong
P
, Gil
MM
, Chaiyasit
N
, Cuenca-Gomez
D
, Plasencia
W
, Rolle
V
, et al. Accuracy of placental growth factor alone or in combination with soluble fms-like tyrosine kinase-1 or maternal factors in detecting preeclampsia in asymptomatic women in the second and third trimesters: a systematic review and meta-analysis
. Am J Obstet Gynecol
. 2023
;229
(3
):222
–47
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
